Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Imaging Studies IV: Magnetic Resonance Imaging01:27

Imaging Studies IV: Magnetic Resonance Imaging

320
Introduction:Magnetic Resonance Imaging, or MRI, can include a specialized imaging technique of the urinary system known as Magnetic Resonance Urography (MRU). This radiation-free technique uses strong magnetic fields and radio waves to produce detailed images with the help of a computer. MRU is particularly effective for visualizing fluid-filled structures like the kidneys, ureters, and bladder.Applications of MRI in the Genitourinary SystemKidneys and Ureters: MRI detects tumors, cysts,...
320
Renal Drug Clearance: Comparison Between Renal Excretion Methods01:08

Renal Drug Clearance: Comparison Between Renal Excretion Methods

698
Renal clearance is a critical parameter encompassing kidney filtration, secretion, and reabsorption processes. It is calculated using a specific equation to determine the rate at which the kidneys clear a drug.
Renal clearance is often associated with the renal glomerular filtration rate (GFR), which represents the rate at which plasma is filtered through the glomeruli in the kidney. When drug reabsorption is minimal and there is no active secretion, renal clearance is closely related to the...
698
Renal Drug Clearance: Overview01:06

Renal Drug Clearance: Overview

898
Renal clearance is a crucial parameter in pharmacokinetics that quantifies the rate at which the kidneys excrete a drug. It represents a constant fraction of the central volume of distribution containing the drug that the kidney eliminates per unit of time.
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
898
Magnetic Resonance Imaging01:24

Magnetic Resonance Imaging

10.1K
Magnetic resonance imaging (MRI) is a noninvasive medical imaging technique based on a phenomenon of nuclear physics discovered in the 1930s, in which matter exposed to magnetic fields and radio waves was found to emit radio signals. In 1970, a physician and researcher named Raymond Damadian noticed that malignant (cancerous) tissue gave off different signals than normal body tissue. He applied for a patent for the first MRI scanning device in clinical use by the early 1980s. The early MRI...
10.1K
Determination of Renal Drug Clearance: Graphical and Midpoint Methods01:07

Determination of Renal Drug Clearance: Graphical and Midpoint Methods

445
Renal clearance, a crucial parameter in pharmacokinetics, can be determined using two different methods: the graphical method and the midpoint method. These methods provide insights into the rate of drug excretion by the kidneys and aid in assessing renal function.
The graphical method involves plotting the rate of drug excretion in urine against the plasma drug concentration. By analyzing the graph, the clearance can be calculated and obtained. Drugs rapidly excreted by the kidneys exhibit a...
445
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

284
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
284

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preoperative MRI Model for Predicting Inferior Vena Cava Wall Invasion in Renal Cell Carcinoma with Tumor Thrombus.

Radiology. Imaging cancer·2026
Same author

MRI enhancement characteristics of septa and walls improve risk stratification of Bosniak III cystic renal masses.

Abdominal radiology (New York)·2026
Same author

Evaluating Malignancy Detection in Small Renal Masses: Integrating the Pseudocapsule Into the Clear Cell Likelihood Score.

Journal of magnetic resonance imaging : JMRI·2026
Same author

Preoperative Assessment of Extraprostatic Extension in Prostate Cancer Using an Interpretable Tabular Prior-Data Fitted Network-Based Radiomics Model From MRI.

Journal of magnetic resonance imaging : JMRI·2025
Same author

Cystitis glandularis: MR imaging characteristics in 27 patients.

Japanese journal of radiology·2024
Same author

Differentiating mixed epithelial and stromal tumor family from predominantly cystic renal cell carcinoma using magnetic resonance imaging-based Bosniak classification system version 2019.

Japanese journal of radiology·2024

Related Experiment Video

Updated: Feb 28, 2026

Dynamic Contrast Enhanced Magnetic Resonance Imaging of an Orthotopic Pancreatic Cancer Mouse Model
06:24

Dynamic Contrast Enhanced Magnetic Resonance Imaging of an Orthotopic Pancreatic Cancer Mouse Model

Published on: April 18, 2015

15.8K

Dynamic Contrast-enhanced MRI in Renal Tumors: Common Subtype Differentiation using Pharmacokinetics.

Hai-Yi Wang1, Zi-Hua Su2, Xiao Xu3

  • 1Department of Radiology, Chinese PLA General Hospital, No.28 Fuxing Road, Haidian District, Beijing, 100853, China.

Scientific Reports
|June 10, 2017
PubMed
Summary

Dynamic contrast-enhanced MRI (DCE-MRI) pharmacokinetic data can differentiate renal tumor subtypes. This study shows Ktrans values effectively distinguish clear cell renal cell carcinoma and fat-poor angiomyolipoma from other subtypes.

More Related Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.8K
In Vivo, Percutaneous, Needle Based, Optical Coherence Tomography of Renal Masses
09:31

In Vivo, Percutaneous, Needle Based, Optical Coherence Tomography of Renal Masses

Published on: March 30, 2015

9.3K

Related Experiment Videos

Last Updated: Feb 28, 2026

Dynamic Contrast Enhanced Magnetic Resonance Imaging of an Orthotopic Pancreatic Cancer Mouse Model
06:24

Dynamic Contrast Enhanced Magnetic Resonance Imaging of an Orthotopic Pancreatic Cancer Mouse Model

Published on: April 18, 2015

15.8K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.8K
In Vivo, Percutaneous, Needle Based, Optical Coherence Tomography of Renal Masses
09:31

In Vivo, Percutaneous, Needle Based, Optical Coherence Tomography of Renal Masses

Published on: March 30, 2015

9.3K

Area of Science:

  • Radiology and Urology
  • Oncology
  • Medical Imaging

Background:

  • Preoperative differentiation of renal tumor subtypes is crucial for clinical management.
  • Dynamic contrast-enhanced MRI (DCE-MRI) offers pharmacokinetic data to assess tumor vascular permeability.

Purpose of the Study:

  • To evaluate the utility of DCE-MRI pharmacokinetic parameters, specifically Ktrans and Ve, in differentiating common renal tumor subtypes.
  • To assess the diagnostic performance of Ktrans in distinguishing clear cell renal cell carcinoma (ccRCC) and fat-poor angiomyolipoma (fpAML) from other subtypes.

Main Methods:

  • A prospective study involving 100 patients with five common renal tumor subtypes: ccRCC (n=65), papillary renal cell carcinoma (pRCC; n=12), chromophobic renal cell carcinoma (cRCC; n=9), uroepithelial carcinoma (UEC; n=14), and fpAML (n=10).
  • Analysis of pharmacokinetic data, including Ktrans and Ve, derived from DCE-MRI.
  • Statistical analysis to compare Ktrans values among subtypes and assess diagnostic accuracy.

Main Results:

  • Significant differences in Ktrans values were observed among ccRCC, pRCC, cRCC, UEC, and fpAML.
  • Ve values did not show significant differences across the studied subtypes.
  • Ktrans achieved 76.9% sensitivity and 71.4% specificity in distinguishing ccRCC from non-ccRCC (pRCC & cRCC).
  • Ktrans demonstrated 100% sensitivity and 76.2% specificity in differentiating fpAML from non-ccRCC.

Conclusions:

  • DCE-MRI pharmacokinetics, particularly Ktrans, show promise for the differential diagnosis of renal tumors.
  • Ktrans is valuable for RCC subtype characterization and differentiating fpAML from non-ccRCC, potentially aiding treatment decisions.